|
|
Vaccine Comparison
|
L. donovani DNA Vaccine encoding KMP-11 |
| Vaccine Information |
|
|
| References |
Bhaumik et al., 2009: Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine. 2009; 27(9); 1306-1316. [PubMed: 19162111].
|
|
L. major DNA vaccine encoding TSA, LMSTI1, KMP11, and LACK |
| Vaccine Information |
- Vaccine Name: L. major DNA vaccine encoding TSA, LMSTI1, KMP11, and LACK
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: Human
- KMP-11
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- TSA
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- LACK
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- LmSTI1
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Vector: pEGFP-N1(Salehi-Sangani et al., 2019)
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
|
|
|
T. cruzi vaccine encoding Tc80 |
| Vaccine Information |
- Vaccine Name: T. cruzi vaccine encoding Tc80
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: Tc80 (Bivona et al., 2018)
- Tc80
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: Intramuscular injection (i.m.)
- Description: T. cruzi sub-unit vaccine formulated with recombinant Tc80 plus oligodeoxynucleotides CpG (ODN-CpG) as adjuvant. (Bivona et al., 2018)
|
| References |
Bivona et al., 2018: Bivona AE, Sánchez Alberti A, Matos MN, Cerny N, Cardoso AC, Morales C, González G, Cazorla SI, Malchiodi EL. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine. PLoS neglected tropical diseases. 2018; 12(3); e0006384. [PubMed: 29601585].
|
|
T. cruzi vaccine encoding TcG2 and TcG4 |
| Vaccine Information |
- Vaccine Name: T. cruzi vaccine encoding TcG2 and TcG4
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: Human
- Antigen: TcG2 and TcG4 (Gupta et al., 2019) - antigens phylogenetically conserved in clinically important T. cruzi strains, expressed in infective and intracellular stages of the parasite, and recognized by parasite-specific cellular and humoral immune responses in multiple T. cruzi-infected hosts (Bhatia et al., 2004).
- G2
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- protein G4
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: Intramuscular injection (i.m.)
- Description: A DNA vaccine containing recombinant proteins TcG2 and TcG4 formulated with fTr (fixed T. rangeli) epimastigotes (Gupta et al., 2019).
|
| References |
Bhatia et al., 2004: Bhatia V, Sinha M, Luxon B, Garg N. Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening. Infection and immunity. 2004; 72(11); 6245-6254. [PubMed: 15501750].
Gupta et al., 2019: Gupta S, Salgado-Jiménez B, Lokugamage N, Vázquez-Chagoyán JC, Garg NJ. TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster Immunization. Frontiers in immunology. 2019; 10; 1456. [PubMed: 31293599].
|
|
T. cruzi Vaccine TcVac2 |
| Vaccine Information |
- Vaccine Name: T. cruzi Vaccine TcVac2
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: Human
- Antigen: TcG1, TcG2, and TcG4 (Gupta and Garg, 2010) - T. cruzi encoding plasmids which have elicited a strong Th1 - type antibody response dominated by immunoglobin G2b (IgG2b)/IgG1 isotypes. (Bhatia and Garg, 2008)
- TcG4
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- G2
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Adjuvant:
- Immunization Route: Intramuscular injection (i.m.)
- Description: TcVAc2 is a DNA-prime/protein-boost subunit vaccine (TcVac2) constituted of candidate antigens (TcG1-, TcG2-, and TcG4) along with adjuvants IL-12 and GM-CSF.(Gupta and Garg, 2010)
|
| References |
Bhatia and Garg, 2008: Bhatia V, Garg NJ. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clinical and vaccine immunology : CVI. 2008; 15(8); 1158-1164. [PubMed: 18550728].
Gupta and Garg, 2010: Gupta S, Garg NJ. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS neglected tropical diseases. 2010; 4(8); e797. [PubMed: 20706586].
|
|
T. cruzi Vaccine TcVac3 encoding TcG2 and TcG4 |
| Vaccine Information |
- Vaccine Name: T. cruzi Vaccine TcVac3 encoding TcG2 and TcG4
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Antigen: TcG2 and TcG4 (Gupta and Garg, 2013) - T. cruzi encoding plasmids which have elicited a strong Th1 - type antibody response dominated by immunoglobin G2b (IgG2b)/IgG1 isotypes. (Bhatia and Garg, 2008)
- G2
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- TcG4
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Adjuvant:
- Vector: plasmid vector (Gupta and Garg, 2013)
- Immunization Route: Intramuscular injection (i.m.)
- Description: DNA-prime/MVA-boost vaccine (TcVac3) constituted of antigenic candidates (TcG2 and TcG4) (Gupta and Garg, 2013)
|
| References |
Bhatia and Garg, 2008: Bhatia V, Garg NJ. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clinical and vaccine immunology : CVI. 2008; 15(8); 1158-1164. [PubMed: 18550728].
Gupta and Garg, 2013: Gupta S, Garg NJ. TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice. PloS one. 2013; 8(3); e59434. [PubMed: 23555672].
|
|
